Maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with chemotherapy and bevacizumab as first-line treatment in patients with advanced colorectal carcinoma.

Trial Profile

Maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with chemotherapy and bevacizumab as first-line treatment in patients with advanced colorectal carcinoma.

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Capecitabine (Primary) ; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms CAIRO-3; CAIRO3
  • Most Recent Events

    • 12 Sep 2017 Results of impact of sarcopenia on dose-limiting toxicities in patients from CAIRO3 study presented at the 42nd European Society for Medical Oncology Congress
    • 01 Sep 2017 Results of post-hoc subgroup analysis, published in the Annals of Oncology.
    • 06 Jun 2017 Results assessing skeletal muscle index loss in 416 CAIRO3 patients presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top